Abeona Therapeutics Inc (ABEO.OQ)
20 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2015||Executive Chairman of the Board|
|2018||President, Chief Scientific Officer, Director|
|55||2018||Chief Executive Officer|
|54||2017||Chief Operating Officer|
|64||2016||Senior Vice President - Research and Development|
- BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease
- BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer
- BRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer
- BRIEF-Abeona Therapeutics Reports Q4 Loss Per Share $0.19
- BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease